Takeda Pharmaceutical Company Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TKPHF research report →
Companywww.takeda.com
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands.
- CEO
- Christophe Weber
- IPO
- 2008
- Employees
- 49,281
- HQ
- Tokyo, JP
Price Chart
Valuation
- Market Cap
- $49.48B
- P/E
- 42.65
- P/S
- 1.84
- P/B
- 1.05
- EV/EBITDA
- 8.87
- Div Yield
- 3.82%
Profitability
- Gross Margin
- 58.76%
- Op Margin
- 10.54%
- Net Margin
- 4.26%
- ROE
- 2.61%
- ROIC
- 2.59%
Growth & Income
- Revenue
- $4.53T · -1.04%
- Net Income
- $192.97B · 78.79%
- EPS
- $123.03 · 79.97%
- Op Income
- $543.85B
- FCF YoY
- 13.28%
Performance & Tape
- 52W High
- $39.20
- 52W Low
- $26.30
- 50D MA
- $33.99
- 200D MA
- $31.21
- Beta
- 0.10
- Avg Volume
- 5.60K
Get TickerSpark's AI analysis on TKPHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TKPHF Coverage
We haven't published any research on TKPHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TKPHF Report →